By Justin Kadis
As the pharmaceutical industry has diversified, there has been a shift in the way facilities are structured. The industry has begun to lean toward wider adoption of multi-product or flexible facilities in an effort to maximize production and prove to customers that any request can be fulfilled by a singular company that is not bound to traditional methods of production.
Many pharmaceutical companies are looking to concentrate their outsourcing to one or a few contract firms that can handle the bulk of their production needs. If a contract developing and manufacturing organization (CDMO) is able to front-load the majority of their drug development and production, the pharmaceutical company sponsor eliminates major risks in the supply chain that can result from employing too many partners at all phases.